Abstract 1854P
Background
Impaired perception of time has been associated with many psychiatric and neurological diseases. Time perception has been studied with different validated scales in the literature. However, the length of these scales limits its feasibility. The aim of our study was to evaluate the relationship of “1 minute” time perception with depression and anxiety in cancer patients receiving chemotherapy.
Methods
The cancer patients receiving active systemic therapy were included in the study. Time perception assessment was performed by testing how they perceived the 1-minute period. The patients were asked to guess the length of 1 minute by using a chronometer. Time perception duration (TPD) were recorded. The median 39 seconds was used to categorize patients as fast and slow time perception. Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale (HADS).
Results
In the study; 242 patients with a median age of 61 (33-88 years) were evaluated. In the TPD evaluation, the median estimation time was 39s (7-135sec) and 50.4% was found to be rapid time perception (<39sec). Anxiety and depression scores were recorded as high in 12% of the patients. There was no significant correlation between TPD and anxiety (r=0.027, p=0.68) and depression scores (r= 0.017, p= 0.79). TPD was similar between the groups with high and normal anxiety scores (39 vs 39 sec, p= 0.90) and those with short perception patients were similar in both groups (51.7% vs 50.2%, p=0.51). TPD was shorter in those with high depression scores (34 vs 40s, p= 0.37). Those with rapid TDP were more common in these patients, but this did not reach statistical significance (58.6% vs 49.3%, p= 0.22). In the multivariate analysis. Female gender and low income were found to be risk factors for high anxiety scores.
Conclusions
The 1-minute time perception assessment could not be shown to be effective in predicting depression and anxiety scores. In our study, in which the group with high depression/anxiety scores was low, the small sample size may be the reason for the insignificant result. Testing the efficacy of 1 minute time perception in larger groups can provide important data to the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05